HC Wainwright reissued their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL - Free Report) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $40.00 price target on the biotechnology company's stock.
Separately, D. Boral Capital restated a "buy" rating and issued a $46.00 target price on shares of Anavex Life Sciences in a research note on Monday.
Check Out Our Latest Research Report on Anavex Life Sciences
Anavex Life Sciences Price Performance
Anavex Life Sciences stock traded up $0.04 during mid-day trading on Wednesday, hitting $9.08. The company's stock had a trading volume of 1,061,924 shares, compared to its average volume of 1,205,851. Anavex Life Sciences has a 52-week low of $3.25 and a 52-week high of $10.45. The company has a market cap of $769.98 million, a PE ratio of -18.10 and a beta of 0.60. The firm's 50 day moving average is $6.54 and its 200 day moving average is $5.62.
Institutional Investors Weigh In On Anavex Life Sciences
Hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in Anavex Life Sciences in the 2nd quarter valued at approximately $57,000. Orion Capital Management LLC increased its position in Anavex Life Sciences by 666.7% during the third quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company's stock worth $65,000 after acquiring an additional 10,000 shares during the period. PVG Asset Management Corp bought a new stake in Anavex Life Sciences in the 3rd quarter valued at $74,000. Atria Investments Inc acquired a new stake in Anavex Life Sciences in the 3rd quarter worth $76,000. Finally, Fiduciary Alliance LLC increased its holdings in shares of Anavex Life Sciences by 45.2% during the 2nd quarter. Fiduciary Alliance LLC now owns 19,275 shares of the biotechnology company's stock worth $80,000 after purchasing an additional 6,000 shares during the period. 31.55% of the stock is owned by institutional investors and hedge funds.
About Anavex Life Sciences
(
Get Free Report)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
See Also
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
